Cidara Therapeutics, Inc. Aktie News

Cidara Therapeutics' CD388 is a long-acting influenza antiviral aimed at providing universal protection with a single yearly dose for each flu season. In contrast to vaccines, CD388's efficacy is not dependent on circulating strains or on an intact patient immune system. CD388 is ideal for pandemic preparedness and for high-risk patients. Readout of a randomized ph2b trial of CD388 is expected ...

SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that it will host a virtual research and development (R&D) day on Thursday, May 22, 2025, from 10:00 to 11:30 AM ET. To register, click here.

SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below investor conferences. Event: RBC Global Healthcare Conference Date: Wednesday, May 21, 2025 Time: 10:00 AM ET Event: Jefferie...

Cidara Therapeutics, Inc. (NASDAQ:CDTX ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Brian Ritchie - LifeSci Advisors Jeffrey Stein - President and Chief Executive Officer Frank Karbe - Chief Financial Officer Nicole Davarpanah - Chief Medical Officer Les Tari - Chief Scientific Officer Jim Beitel - Chief Business Officer Conference Call Participants Eric Schmid...

SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today reported financial results for the first quarter ended March 31, 2025, and provided recent business updates.

We initiate coverage on Cidara Therapeutics with a Strong Buy rating due to its strategic pivot to antiviral CD388 and promising Phase 2b trial data. Rezafungin's successful approval and divestiture to Mundipharma validate Cidara's development capabilities and free resources for advancing CD388. CD388 shows potential for season-long influenza protection, with promising Phase 2a data and a well-...

SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that Nicole Davarpanah, M.D., J.D. has been promoted to chief medical officer (CMO), and Corrina Pavetto has been promoted to senior vice president, clinical development, effectiv...

SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in The Citizens Life Sciences Conference. Details are as follows: Event: The Citizens Life Sciences Conference Date: Wednesday, May 7, 2...